loadpatents
name:-0.44063305854797
name:-0.70166707038879
name:-0.19344711303711
Shuman; Stewart Patent Filings

Shuman; Stewart

Patent Applications and Registrations

Patent applications and USPTO patent grants for Shuman; Stewart.The latest application filed is for "use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors".

Company Profile
13.22.28
  • Shuman; Stewart - New York NY
  • Shuman; Stewart - Carlsbad CA
*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Patent Activity
PatentDate
Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
Grant 11,426,460 - Deng , et al. August 30, 2
2022-08-30
Use Of Mva Or Mvadeltae3l As Immunotherapeutic Agents Against Solid Tumors
App 20220211785 - DENG; Liang ;   et al.
2022-07-07
Vaccinia Virus Mutants Useful For Cancer Immunotherapy
App 20220186192 - Deng; Liang ;   et al.
2022-06-16
Recombinant MVA or MVA.DELTA.E3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
Grant 11,285,209 - Deng , et al. March 29, 2
2022-03-29
Recombinant Poxviruses For Cancer Immunotherapy
App 20220056475 - DENG; Liang ;   et al.
2022-02-24
Use of MVA or MVA.DELTA.E3L as immunotherapeutic agents against solid tumors
Grant 11,253,560 - Deng , et al. February 22, 2
2022-02-22
Vaccinia virus mutants useful for cancer immunotherapy
Grant 11,242,509 - Deng , et al. February 8, 2
2022-02-08
Heat-inactivated Vaccinia Virus As A Vaccine Immune Adjuvant
App 20210177964 - DENG; Liang ;   et al.
2021-06-17
Oncolytic Vaccinia Virus Expressing Immune Checkpoint Blockade For Cancer Immunotherapy
App 20210023151 - DENG; Liang ;   et al.
2021-01-28
Vaccinia Virus Mutants Useful For Cancer Immunotherapy
App 20200339959 - Deng; Liang ;   et al.
2020-10-29
Recombinant Mva Or Mvadele3l Expressing Human Flt3l And Use Thereof As Immuno-therapeutic Agents Against Solid Tumors
App 20200316198 - DENG; Liang ;   et al.
2020-10-08
Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human FLT3L or GM-CSF for cancer immunotherapy
Grant 10,765,711 - Deng , et al. Sep
2020-09-08
Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
Grant 10,736,962 - Deng , et al. A
2020-08-11
Use Of Inactivated Nonreplicating Modified Vaccinia Virus Ankara (mva) As Monoimmunotherapy Or In Combination With Immume Checkp
App 20200237902 - Deng; Liang ;   et al.
2020-07-30
Replication Competent Attenuated Vaccinia Viruses With Deletion Of Thymidine Kinase With And Without The Expression Of Human Flt
App 20200237839 - DENG; Liang ;   et al.
2020-07-30
Use Of Mva Or Mvadeltae3l As Immunotherapeutic Agents Against Solid Tumors
App 20200222479 - DENG; Liang ;   et al.
2020-07-16
Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
Grant 10,639,366 - Deng , et al.
2020-05-05
Use of MVA or MVA.DELTA.E3L as immunotherapeutic agents against solid tumors
Grant 10,548,930 - Deng , et al. Fe
2020-02-04
Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
Grant 10,512,662 - Deng , et al. Dec
2019-12-24
Replication Competent Attenuated Vaccinia Viruses With Deletion Of Thymidine Kinase With And Without The Expression Of Human Flt3l Or Gm-csf For Cancer Immunotherapy
App 20190054131 - DENG; Liang ;   et al.
2019-02-21
Recombinant Mva Or Mvadele3l Expressing Human Flt3l And Use Thereof As Immuno-therapeutic Agents Against Solid Tumors
App 20190046640 - DENG; Liang ;   et al.
2019-02-14
Use Of Inactivated Nonreplicating Modified Vaccinia Virus Ankara (mva) As Monoimmunotherapy Or In Combination With Immume Checkpoint Blocking Agents For Solid Tumors
App 20180236062 - Deng; Liang ;   et al.
2018-08-23
Use Of Mva Or Mvadeltae3l As Immunotherapeutic Agents Against Solid Tumors
App 20180078591 - DENG; Liang ;   et al.
2018-03-22
Methods And Reagents For Molecular Cloning
App 20150093788 - CHESNUT; Jonathan ;   et al.
2015-04-02
Method for molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomerase
Grant 8,551,739 - Shuman October 8, 2
2013-10-08
Covalent Joining of DNA Strands to RNA Strands Catalyzed by Vaccinia Topoisomerase
App 20120322109 - SHUMAN; STEWART ;   et al.
2012-12-20
Covalent joining of DNA strands to RNA strands catalyzed by vaccinia topoisomerase
Grant 8,192,932 - Shuman , et al. June 5, 2
2012-06-05
Methods And Reagents For Molecular Cloning
App 20120129225 - Chesnut; Jonathan D. ;   et al.
2012-05-24
Covalent joining of DNA strands to RNA strands catalyzed by vaccinia topoisomerase
App 20100317064 - Shuman; Stewart ;   et al.
2010-12-16
Covalent joining of DNA to RNA by vaccinia topoisomerase and uses thereof
Grant 7,662,556 - Shuman , et al. February 16, 2
2010-02-16
Methods And Reagents For Molecular Cloning
App 20090328244 - Chesnut; Jonathan D. ;   et al.
2009-12-31
Method for molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomerase
Grant 7,550,295 - Shuman June 23, 2
2009-06-23
Methods and reagents for molecular cloning
Grant 7,528,241 - Chesnut , et al. May 5, 2
2009-05-05
Method for molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomerase
App 20090068708 - Shuman; Stewart
2009-03-12
Method for molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomerase
App 20060160072 - Shuman; Stewart
2006-07-20
Pharmacological targeting of bacterial DNA ligase for treatment and prevention of bacterial infections
App 20060134642 - Shuman; Stewart ;   et al.
2006-06-22
Topoisomerase-based reagents and methods for molecular cloning
Grant 7,026,141 - Shuman April 11, 2
2006-04-11
Methods and reagents for molecular cloning
App 20050282184 - Chesnut, Jonathan D. ;   et al.
2005-12-22
Methods and reagents for molecular cloning
Grant 6,916,632 - Chesnut , et al. July 12, 2
2005-07-12
Pharmacological targeting of mRNA cap formation for treatment of parasitic infections
Grant 6,844,167 - Shuman , et al. January 18, 2
2005-01-18
Pharmacological targeting of bacterial DNA ligase for treatment and prevention of bacterial infections
Grant 6,787,341 - Shuman , et al. September 7, 2
2004-09-07
Covalent joining of DNA to RNA by vaccinia topoisomerase and uses thereof
App 20040058417 - Shuman, Stewart ;   et al.
2004-03-25
Topoisomerase-based ligation and cloning methods
Grant 6,653,106 - Shuman , et al. November 25, 2
2003-11-25
Topoisomerase-based reagents and methods for molecular cloning
App 20030215925 - Shuman, Stewart
2003-11-20
Pharmacological targeting of mRNA cap formation for treatment of parasitic infections
App 20030166209 - Shuman, Stewart ;   et al.
2003-09-04
Pharmacological targeting of bacterial DNA ligase for treatment and prevention of bacterial infections
App 20030036647 - Shuman, Stewart ;   et al.
2003-02-20
Methods and reagents for molecular cloning
App 20030022179 - Chesnut, Jonathan D. ;   et al.
2003-01-30
Pharmacological targeting of mRNA cap formation
Grant 6,232,070 - Shuman May 15, 2
2001-05-15
Method for molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomerase
Grant 5,766,891 - Shuman June 16, 1
1998-06-16

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed